North America viral vectors and plasmid DNA manufacturing market was valued at USD 2.82 billion in 2025 and is projected to reach USD 10.64 billion by 2035, growing at a CAGR of 14.20%, driven by rising gene therapy demand and biopharma advancements.

North America Viral Vectors and Plasmid DNA Manufacturing Market Statical Scope

North America has seen major growth in the viral vector and plasmid DNA manufacturing market by capturing the largest market share in 2024. This prominence is attributed to the strong presence of leading pharmaceutical and biotechnology companies that are actively engaged in the development of gene and cell therapies . The region benefits from an advanced healthcare infrastructure, substantial investments in research and development, and supportive regulatory frameworks that facilitate the rapid approval and commercialization of innovative treatments. Furthermore, the high volume of ongoing clinical trials and the early adoption of cutting-edge biotechnologies have significantly driven the demand for viral vectors and plasmid DNA.

North America Viral Vectors and Plasmid DNA Manufacturing Market Share, By Vector Type, 2025 (%)

• Adeno-associated virus (AAV)- Adeno-associated virus (AAV) leads the market, with a share of 30%, driven by its strong safety profile, high efficiency in gene delivery, and low immunogenicity.
• Lentivirus- Lentivirus holds a significant portion, with a share of 22%, supported by rising demand for CAR-T cell therapies and stable gene transfer capabilities.
• Adenovirus- Adenovirus represents a segment, with a share of 16%, supported by its use in vaccine development, COVID-19 vaccine production and gene delivery applications.
• Plasmids- Plasmids account for a notable share of 17%, driven by increasing demand in DNA-based therapeutics and manufacturing support applications.

North America Viral Vectors and Plasmid DNA Manufacturing Market Share, By Workflow, 2025 (%)

• Upstream manufacturing- Upstream manufacturing dominates the market, with a share of 58%, driven by increasing demand for vector production, cell culture processes, and its scalable process.
• Downstream manufacturing- Downstream manufacturing holds a significant portion, with a share of 42%, supported by the growing need for purification, processing, and quality control activities.

North America Viral Vectors and Plasmid DNA Manufacturing Market Share, By Application, 2025 (%)

• Gene therapy- Gene therapy leads the market, with a share of 34%, driven by increasing clinical development activity, advanced therapies and the growing commercialization of gene-based treatments.
• Antisense & RNAi therapy- Antisense & RNAi therapy holds a share of 10%, driven by increasing focus on next-generation therapeutic approaches.
• Cell therapy- Cell therapy holds a significant share of 24%, supported by increasing investment in advanced therapies and expanding therapeutic pipelines.
• Vaccinology- Vaccinology represents a segment, with a share of 14%, supported by demand for viral vectors in vaccine development and production.
• Research application- Research applications account for a notable share of 18%, driven by increased research investment and preclinical development activities.

North America Viral Vectors and Plasmid DNA Manufacturing Market Share, By End-use, 2025 (%)

• Pharmaceutical and biopharmaceutical companies- Pharmaceutical and biopharmaceutical companies dominate the market, with a share of 72%, driven by strong outsourcing demand and large-scale production requirements
• Research institutes- Research institutes hold a significant share of 28%, supported by ongoing research activities and the development of novel vector technologies.

North America Viral Vectors and Plasmid DNA Manufacturing Market Share, By Disease, 2025 (%)

• Cancer- Cancer dominates the market, with a share of 34%, driven by significant focus on the use of gene and cell therapies in oncology.
• Genetic disorders- Genetic disorders hold a substantial portion, with a share of 28%, supported by rising therapeutic development targeting rare and inherited conditions.
• Infectious diseases- Infectious diseases account for a notable share of 24%, driven by continued investment in vaccine and antiviral therapeutic development.

Top Companies in the North America Viral Vectors and Plasmid DNA Manufacturing Market

• Merck KGaA
• Lonza
• FUJIFILM Diosynth Biotechnologies
• Thermo Fisher Scientific
• Cobra Biologics
• Catalent Inc.
• Wuxi Biologics
• Takara Bio Inc.
• Waisman Biomanufacturing
• Genezen laboratories
• Batavia Biosciences
• Miltenyi Biotec GmbH
• SIRION Biotech GmbH
• Virovek Incorporation
• BioNTech IMFS GmbH
• Audentes Therapeutics
• BioMarin Pharmaceutical
• RegenxBio, Inc.

Segments Covered in the Report

By Vector Type

• Adeno-associated virus (AAV)
• Lentivirus
• Adenovirus
• Retrovirus
• Plasmids
• Others

By Workflow

• Upstream Manufacturing
• Downstream Manufacturing

By Application

• Antisense & RNAi Therapy
• Gene Therapy
• Cell Therapy
• Vaccinology
• Research Applications

By End Use

• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes

By Disease

• Cancer
• Genetic Disorders
• Infectious Diseases
• Others